ReviewTranslational pediatrics2025
An illustrated history of fetal surgery for myelomeningocele.
Review in Translational pediatrics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Today, fetal surgery for myelomeningocele (MMC) is the standard of care. From the initial concept to accepted practice, the story of fetal MMC (fMMC) repair involves innovation, persistence, collaboration, rigor, and courage. This illustrated history traces the pivotal moments, key figures, crucial relationships, and groundbreaking research that gave rise to this transformative operation in the United States. Beginning with Dr. Michael Harrison's "crazy idea" of fetal surgery in 1969, each decade brought advancements essential to the success of fMMC repair. The 1970s saw technological improvements in fetal ultrasonography and fetoscopy. The 1980s were marked by the first open fetal surgery, the founding of the International Fetal Medicine and Surgery Society (IFMSS), and the creation of animal models for fMMC. In the 1990s, positive results from animal experiments paved the way for the first successful human fMMC repairs, made possible through close collaboration among multidisciplinary teams. The 2000s were defined by the landmark MOMS trial, confirming the benefits of fetal repair and establishing its role in clinical practice. The 2010s witnessed rapid global expansion, with fetal MMC repair programs emerging in Europe, Latin America, and beyond, often adapting techniques for resource-limited settings. A resurgence in the fetoscopic approach further broadened the field, aiming to reduce maternal morbidity while preserving fetal benefit. Today, the legacy of this operation is reflected in the improved outcomes and quality of life of children and families worldwide, and in the enduring spirit of innovation and collaboration that continues to advance fetal therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.